Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Daniil S AbramchukChemistry Department, Lomonosov Moscow State University, Leninskie Gory 1,3, 119991 Moscow, Russia.ORCID 0009-0000-3664-2978
Olga O KrasnovskayaChemistry Department, Lomonosov Moscow State University, Leninskie Gory 1,3, 119991 Moscow, Russia.ORCID 0000-0002-4948-2747
Alevtina S VoskresenskayaChemistry Department, Lomonosov Moscow State University, Leninskie Gory 1,3, 119991 Moscow, Russia.ORCID 0009-0002-0752-1303
Alexander N VaneevChemistry Department, Lomonosov Moscow State University, Leninskie Gory 1,3, 119991 Moscow, Russia.ORCID 0000-0001-8201-8498
Regina M KuanaevaLaboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia.ORCID 0009-0003-1948-7381
Vugara V Mamed-NabizadeLaboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia.ORCID 0000-0001-8460-4685
Vasilii S KolmogorovChemistry Department, Lomonosov Moscow State University, Leninskie Gory 1,3, 119991 Moscow, Russia.ORCID 0000-0002-7135-8910
Olga I KechkoEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str. 32, 117292 Moscow, Russia.
Vladimir A MitkevichEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str. 32, 117292 Moscow, Russia.ORCID 0000-0002-1517-1983
Alexander A MakarovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str. 32, 117292 Moscow, Russia.ORCID 0000-0001-6220-6969
Alexei A NastenkoLaboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia.ORCID 0009-0005-3793-4813
Maxim A AbakumovDepartment of Medical Nanobiotechnology, N.I. Pirogov Russian National Research Medical University, Ostrovityanova Str., 1, 6, 117997 Moscow, Russia.ORCID 0000-0003-2622-9201
Petr V GorelkinLaboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia.ORCID 0000-0002-4860-9013
Sergei V SalikhovLaboratory of Biophysics, National University of Science and Technology (MISIS), Leninskiy Prospect 4, 119049 Moscow, Russia.
Elena K BeloglazkinaChemistry Department, Lomonosov Moscow State University, Leninskie Gory 1,3, 119991 Moscow, Russia.ORCID 0000-0001-6796-8241
Alexander S ErofeevChemistry Department, Lomonosov Moscow State University, Leninskie Gory 1,3, 119991 Moscow, Russia.ORCID 0000-0002-6631-821X
Funding
Russian Science Foundation 19-74-30007
6 · The paper itself
Abstract
Alzheimer's disease (AD) is a worldwide problem due to the lack of effective therapy and accurate methods for timely diagnosis. The complexity of AD's pathophysiology complicates the development of effective therapeutic agents, as most drugs act on only one therapeutic target, bypassing others. The design and development of multifunctional agents capable of altering metal ion-induced abnormalities, oxidative stress, and toxic beta amyloid (Aβ) aggregates is of interest. Herein, we report the first boron dipyrromethene (BODIPY) based bifunctional copper chelator with clioquinol, BDP-CLQ, capable of both optical detection of Aβ fibrils and copper chelation, with multiple anti-AD properties. Foremost, BDP-CLQ demonstrated a 3-fold and 5-fold fluorescence increase at 650 nm and 565 nm in the presence of Aβ and effective copper chelation (pK
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Bifunctional BODIPY-Clioquinol Copper Chelator with Multiple Anti-AD Properties. · full record | Socratic